 Michael Rosenberg
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 11 | 2023 | 324 | 3.780 |
Why?
| | Long QT Syndrome | 7 | 2023 | 59 | 3.760 |
Why?
| | Machine Learning | 8 | 2023 | 318 | 2.400 |
Why?
| | Electronic Health Records | 5 | 2022 | 801 | 1.630 |
Why?
| | Anti-Arrhythmia Agents | 3 | 2023 | 106 | 1.510 |
Why?
| | Body Height | 5 | 2017 | 180 | 1.400 |
Why?
| | Electrocardiography | 9 | 2023 | 562 | 1.210 |
Why?
| | Defibrillators, Implantable | 7 | 2020 | 286 | 1.070 |
Why?
| | Torsades de Pointes | 3 | 2021 | 17 | 0.950 |
Why?
| | Death, Sudden, Cardiac | 6 | 2019 | 160 | 0.860 |
Why?
| | Tachycardia, Ventricular | 4 | 2022 | 153 | 0.830 |
Why?
| | Arrhythmias, Cardiac | 4 | 2019 | 278 | 0.800 |
Why?
| | Medical Order Entry Systems | 1 | 2021 | 41 | 0.720 |
Why?
| | Phenethylamines | 1 | 2019 | 17 | 0.690 |
Why?
| | Sotalol | 1 | 2019 | 4 | 0.690 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 1892 | 0.670 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 168 | 0.640 |
Why?
| | Tachycardia, Supraventricular | 2 | 2021 | 42 | 0.630 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2022 | 287 | 0.620 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 176 | 0.620 |
Why?
| | Dihydrotestosterone | 1 | 2018 | 39 | 0.610 |
Why?
| | Risk Assessment | 5 | 2021 | 2973 | 0.590 |
Why?
| | Pacemaker, Artificial | 4 | 2023 | 107 | 0.580 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2019 | 54 | 0.570 |
Why?
| | Multifactorial Inheritance | 1 | 2017 | 125 | 0.540 |
Why?
| | Sulfonamides | 1 | 2019 | 445 | 0.540 |
Why?
| | Decision Support Techniques | 1 | 2019 | 351 | 0.530 |
Why?
| | Heart Rate | 1 | 2019 | 704 | 0.530 |
Why?
| | Peptide Fragments | 3 | 2014 | 668 | 0.500 |
Why?
| | Aged | 18 | 2023 | 19094 | 0.500 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2015 | 359 | 0.480 |
Why?
| | Endonucleases | 1 | 2014 | 30 | 0.470 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2014 | 11 | 0.470 |
Why?
| | Risk Factors | 15 | 2023 | 8627 | 0.470 |
Why?
| | Procollagen | 1 | 2014 | 19 | 0.460 |
Why?
| | Heart Failure | 2 | 2023 | 1952 | 0.460 |
Why?
| | Humans | 42 | 2023 | 114757 | 0.450 |
Why?
| | Myocardial Infarction | 1 | 2020 | 927 | 0.440 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 153 | 0.430 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 1197 | 0.420 |
Why?
| | Incidence | 6 | 2021 | 2312 | 0.420 |
Why?
| | Heart Failure, Diastolic | 1 | 2012 | 20 | 0.420 |
Why?
| | Coronary Disease | 1 | 2013 | 347 | 0.380 |
Why?
| | Male | 25 | 2023 | 55579 | 0.380 |
Why?
| | Atrioventricular Block | 2 | 2023 | 37 | 0.370 |
Why?
| | Female | 24 | 2022 | 59507 | 0.370 |
Why?
| | Cardiomyopathies | 1 | 2014 | 298 | 0.360 |
Why?
| | Atherosclerosis | 1 | 2013 | 342 | 0.350 |
Why?
| | Catheter Ablation | 3 | 2022 | 291 | 0.330 |
Why?
| | Transcatheter Aortic Valve Replacement | 2 | 2023 | 152 | 0.330 |
Why?
| | Exercise | 2 | 2018 | 1644 | 0.320 |
Why?
| | Aortic Valve Stenosis | 2 | 2023 | 272 | 0.300 |
Why?
| | Proportional Hazards Models | 5 | 2018 | 1080 | 0.280 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2099 | 0.280 |
Why?
| | Middle Aged | 12 | 2023 | 26757 | 0.280 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2386 | 0.230 |
Why?
| | Logistic Models | 2 | 2020 | 1843 | 0.230 |
Why?
| | Basketball | 1 | 2023 | 14 | 0.220 |
Why?
| | United States | 6 | 2019 | 12176 | 0.220 |
Why?
| | Pilot Projects | 3 | 2018 | 1370 | 0.220 |
Why?
| | Heart Conduction System | 1 | 2023 | 82 | 0.210 |
Why?
| | Prospective Studies | 5 | 2019 | 6217 | 0.210 |
Why?
| | Electric Countershock | 1 | 2023 | 104 | 0.210 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2014 | 96 | 0.200 |
Why?
| | Sex Factors | 3 | 2018 | 1717 | 0.200 |
Why?
| | Ventricular Premature Complexes | 1 | 2022 | 26 | 0.200 |
Why?
| | Metoprolol | 1 | 2022 | 37 | 0.200 |
Why?
| | Diastole | 2 | 2012 | 131 | 0.200 |
Why?
| | Artificial Intelligence | 1 | 2023 | 145 | 0.190 |
Why?
| | Atrial Flutter | 1 | 2021 | 25 | 0.190 |
Why?
| | Retrospective Studies | 10 | 2023 | 12515 | 0.190 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 1 | 2021 | 28 | 0.190 |
Why?
| | Biomarkers | 3 | 2018 | 3416 | 0.190 |
Why?
| | Cluster Analysis | 1 | 2022 | 460 | 0.190 |
Why?
| | Hypertension | 2 | 2022 | 1059 | 0.180 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 21 | 0.170 |
Why?
| | Contraindications, Procedure | 1 | 2019 | 11 | 0.170 |
Why?
| | Myostatin | 2 | 2009 | 26 | 0.170 |
Why?
| | Bradycardia | 1 | 2019 | 48 | 0.160 |
Why?
| | Cell Phone | 1 | 2020 | 76 | 0.160 |
Why?
| | Tachycardia | 2 | 2021 | 50 | 0.160 |
Why?
| | Time Factors | 3 | 2019 | 6124 | 0.160 |
Why?
| | Decision Trees | 1 | 2018 | 80 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2019 | 184 | 0.150 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2018 | 48 | 0.150 |
Why?
| | Adult | 7 | 2023 | 30548 | 0.150 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1796 | 0.150 |
Why?
| | Nonlinear Dynamics | 1 | 2018 | 83 | 0.150 |
Why?
| | Frailty | 1 | 2019 | 114 | 0.140 |
Why?
| | Patient Safety | 1 | 2019 | 278 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2017 | 99 | 0.130 |
Why?
| | Body Weights and Measures | 1 | 2016 | 34 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2020 | 3005 | 0.130 |
Why?
| | Inpatients | 1 | 2019 | 378 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2023 | 9089 | 0.130 |
Why?
| | Down-Regulation | 1 | 2018 | 596 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1846 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 772 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 181 | 0.120 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2015 | 42 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1435 | 0.120 |
Why?
| | Sirtuin 2 | 1 | 2014 | 12 | 0.120 |
Why?
| | Algorithms | 1 | 2021 | 1468 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 231 | 0.110 |
Why?
| | Prosthesis Implantation | 1 | 2015 | 139 | 0.110 |
Why?
| | Primary Prevention | 1 | 2015 | 172 | 0.110 |
Why?
| | Prognosis | 2 | 2018 | 3334 | 0.110 |
Why?
| | Longevity | 1 | 2014 | 137 | 0.110 |
Why?
| | Cardiac Pacing, Artificial | 2 | 2023 | 79 | 0.110 |
Why?
| | Atrial Function, Left | 1 | 2012 | 5 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6350 | 0.110 |
Why?
| | Echocardiography | 1 | 2015 | 554 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4420 | 0.100 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 72 | 0.100 |
Why?
| | Prevalence | 1 | 2018 | 2249 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 797 | 0.100 |
Why?
| | Fibrosis | 1 | 2014 | 453 | 0.100 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 92 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 2890 | 0.090 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2011 | 16 | 0.090 |
Why?
| | Receptors, Thyroid Hormone | 1 | 2011 | 20 | 0.090 |
Why?
| | Population Surveillance | 1 | 2013 | 392 | 0.090 |
Why?
| | Thyroid Hormones | 1 | 2011 | 54 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2009 | 286 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2015 | 709 | 0.090 |
Why?
| | Thyroid Gland | 1 | 2011 | 84 | 0.090 |
Why?
| | Blood Flow Velocity | 1 | 2011 | 387 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 667 | 0.090 |
Why?
| | Heart | 2 | 2010 | 609 | 0.080 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 165 | 0.080 |
Why?
| | Cardiomegaly | 1 | 2010 | 157 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 815 | 0.080 |
Why?
| | Anti-Infective Agents, Local | 1 | 2009 | 40 | 0.080 |
Why?
| | Ventricular Fibrillation | 1 | 2009 | 51 | 0.080 |
Why?
| | Young Adult | 2 | 2023 | 10463 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2019 | 2127 | 0.080 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2009 | 121 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2009 | 185 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 359 | 0.070 |
Why?
| | Gene Deletion | 1 | 2009 | 356 | 0.070 |
Why?
| | Aortic Valve | 2 | 2023 | 400 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 399 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2010 | 448 | 0.070 |
Why?
| | Ethanol | 1 | 2009 | 548 | 0.060 |
Why?
| | Mice | 5 | 2014 | 14916 | 0.060 |
Why?
| | Bundle of His | 1 | 2023 | 16 | 0.060 |
Why?
| | Bundle-Branch Block | 1 | 2023 | 29 | 0.060 |
Why?
| | Nebivolol | 1 | 2022 | 9 | 0.050 |
Why?
| | Atrioventricular Node | 1 | 2021 | 14 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 385 | 0.050 |
Why?
| | Mice, Knockout | 3 | 2014 | 2582 | 0.050 |
Why?
| | Stroke Volume | 1 | 2023 | 508 | 0.040 |
Why?
| | Remote Sensing Technology | 1 | 2020 | 11 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 479 | 0.040 |
Why?
| | Electronics | 1 | 2020 | 67 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1620 | 0.040 |
Why?
| | Body Mass Index | 2 | 2017 | 1958 | 0.040 |
Why?
| | Survival Analysis | 2 | 2014 | 1218 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1151 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 43 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2018 | 307 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1642 | 0.030 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 64 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 946 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 954 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2014 | 84 | 0.030 |
Why?
| | Blood Glucose | 2 | 2016 | 1821 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 4901 | 0.030 |
Why?
| | NAD | 1 | 2014 | 64 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2015 | 226 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4409 | 0.030 |
Why?
| | Animals | 5 | 2014 | 31762 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 727 | 0.030 |
Why?
| | HeLa Cells | 1 | 2014 | 562 | 0.030 |
Why?
| | Lipids | 1 | 2016 | 582 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1774 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2763 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2011 | 42 | 0.020 |
Why?
| | Thyroxine | 1 | 2011 | 58 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2011 | 95 | 0.020 |
Why?
| | Thyrotropin | 1 | 2011 | 99 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2011 | 65 | 0.020 |
Why?
| | Health Behavior | 1 | 2016 | 704 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 293 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 552 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1530 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5035 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4086 | 0.020 |
Why?
| | Hypertrophy | 1 | 2009 | 109 | 0.020 |
Why?
| | Bone Development | 1 | 2009 | 47 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 224 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2010 | 370 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 994 | 0.020 |
Why?
| | Tibia | 1 | 2009 | 166 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 213 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1393 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 928 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 675 | 0.020 |
Why?
| | Bone and Bones | 1 | 2009 | 278 | 0.020 |
Why?
| | Gene Expression | 1 | 2011 | 1420 | 0.020 |
Why?
| | Bone Density | 1 | 2009 | 432 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 1951 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 2639 | 0.010 |
Why?
| | Rats | 1 | 2010 | 4943 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 4710 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2481 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2079 | 0.010 |
Why?
|
|
Rosenberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|